Published by Josh White on 27th May 2021
(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.
URL: http://www.digitallook.com/dl/news/story/31879583/...